Background: Predicting malignancy in intraductal papillary mucinous neoplasm remains challenging. Integrated molecular pathology combines pancreatic fluid DNA and clinical factors into a malignant potential score. We sought to determine the utility of DNA components alone in predicting high-grade dysplasia/invasive disease . Methods: We reviewed prospectively the records from 1,106 patients with intraductal papillary mucinous neoplasm. We excluded non-intraductal papillary mucinous neoplasm cases and cases with definitive malignant cytology. A total 225 patients had 283 DNA profiles (98 followed by surgery, 185 followed by ≥23-month surveillance). High-grade dysplasia/invasive outcomes were high-grade dysplasia, intraductal papillary mucinous neoplasm-invasive, and adenocarcinoma on surgical pathology or mesenteric or vascular invasion, metastases, or biopsy with high-grade dysplasia or adenocarcinoma during surveillance. Results: High-quantity DNA predicted ( P = .004) high-grade dysplasia/invasive disease outcomes with sensitivity of 78.3%, but 52.7% specificity, indicating benign cases may exhibit high-quantity DNA. High clonality loss of heterozygosity of tumor suppressor genes was 98.0% specific, strongly predicted high-grade dysplasia/invasive disease but lacked sensitivity (20.0%). High-quantity DNA + high clonality loss of heterozygosity had 99.0% specificity for high-grade dysplasia/invasive disease. KRAS mutation alone did not predict high-grade dysplasia/invasive disease, but, when combined with high-quantity DNA (specificity 84.7%) and high clonality loss of heterozygosity (specificity 99.0%) strongly predicted high-grade dysplasia/invasive outcomes. Conclusion: Certain DNA components are highly specific for high-grade dysplasia/invasive disease and may indicate aggressive lesions, requiring resection when cytology fails.
imaging, however, IPMN is now appreciated as one of the most common pancreatic cystic neoplasms, representing 24% of cysts resected at a single institution. 2 Thus, the tremendous effort dedicated to understanding IPMN throughout the preceding decades has been warranted.
IPMN may transform through progressive grades of dysplasia, from low, moderate, and high-grade dysplasia (HGD) to invasive IPMN. The 2012 International Consensus Guidelines (ICG) focus on clinical and radiographic criteria to predict the most aggressive lesions necessitating resection, depending on the presence of high-risk stigmata or worrisome features. 3 These consensus guidelines have been noted to provide reasonable sensitivity (72%-90%) but often poor specificity (46%-78%) for detecting HGD or invasive IPMN. 4, 5 For this reason, research dedicated to understanding IPMN at a molecular level has gained favor.
Since the mid-20 0 0s, PancraGEN (Interpace Diagnostics [previously Redpath], Parsippany, NJ) has sought to predict which pancreatic cysts held the greatest potential for malignancy. Pancreatic cyst or ductal fluid gathered via endoscopy is analyzed for the level and quality of DNA, oncogene mutations, and loss of heterozygosity (LOH) of tumor suppressor genes. Clinical data (eg, cyst size, main pancreatic duct diameter, and carcinoembryonic antigen level in the cyst fluid) can be combined with these DNA factors to develop an aggregate malignancy risk score. This testing process is termed integrated molecular pathology (IMP). 6 This integration process makes it difficult to determine the merits of the DNA components alone.
Earlier studies have sought to determine whether DNA features could predict mucinous differentiation, as well as malignancy. Several studies have proposed high-quantity and/or high-quality DNA on pancreatic cyst fluid analysis as a predictor of a nonbenign or malignant course of pancreatic cysts. [7] [8] [9] [10] [11] Mutations of the KRAS oncogene have been studied extensively and are discovered commonly in pancreatic and other cancers 12 ; but, the results of earlier studies, regarding the ability to predict a malignant outcome for pancreatic cysts, are conflicting. 8 , 10-15 The presence of KRAS or GNAS mutations have been determined to be specific for mucinous differentiation of pancreatic cysts, 8,12 , 15-17 with GNAS especially specific for IPMN. 18, 19 Allelic LOH of tumor suppressor genes has also been associated with mucinous differentiation or malignant pathology, 17, 20 especially when in combination with KRAS mutations. 7-11 , 13,21 Studies dedicated to IPMN and especially the surveillance population are lacking, making the application of earlier findings to this specific population unclear. Our study focuses on the predictive capabilities of each DNA component for patients with IPMN specifically, including both surgical and surveillance cohorts.
Methods

Patient selection
We reviewed retrospectively our prospectively maintained database of patients with IPMN ( n = 1,106) from Indiana University (Indianapolis). We queried the database for patients with non-malignant cytology (no definitive HGD or carcinoma) on endoscopic ultrasonographically guided fine-needle aspiration (EUS-FNA) of cyst or duct fluid that had subsequent IMP testing performed. We examined 283 IMP cases (225 patients): 98 cases were followed by surgery; whereas 185 were followed by a minimum of 23 months' surveillance. The surgical cohort was defined by IPMN on surgical pathology specimens corresponding to the anatomic location of cyst fluid analysis. Inclusion in the surveillance cohort required convincing evidence of IPMN (ie, multifocal pancreatic cysts, solitary pancreatic cysts with a connection to the main pancreatic duct or main duct dilation with cytology suggestive of IPMN, cyst fluid mucin, carcinoembryonic antigen > 192ng/mL, or GNAS mutation).
An HGD/invasive outcome included HGD/invasive IPMN, or adenocarcinoma on surgical pathology, malignant cytology on subsequent biopsy, and radiographic/endoscopic evidence of invasive mass lesion or metastatic disease during surveillance.
At our institution, patients diagnosed with pancreatic cysts > 1 cm or main duct dilation not clearly representative of IPMN typically undergo initial EUS-FNA with DNA profiling to establish a baseline diagnosis based on endoscopic appearance, characteristics of the fluid and cytology, and molecular profile. Patients undergoing surveillance are recommended for subsequent testing every 3 or 5 years, based on stratification to a high-or low-risk protocol, respectively. A total 200 μL of fluid are optimal for testing, and coverage varies by insurance. Clinically, patients were selected for operative treatment or surveillance, based primarily on the presence or absence of symptoms, general health and operative candidacy, progression of disease, cytology, and ICG criteria. As the role of DNA profiling is not entirely clear for the IPMN population, these data were not used independently to recommend a management strategy.
Parameters of integrated molecular pathology
In our study, patients with any value other than low-quantity DNA (range: low-greatly elevated) were considered to have "highquantity" DNA. Similarly, patients with any value other than poorquality DNA (range: poor-good) were designated to the "highquality" DNA group. A designation of "high-risk" DNA requires both high-quantity and high-quality DNA. Oncogene mutations (KRAS and GNAS) and allelic LOH are also reported 22 ; these are considered high clonality (HC) when ≥75% of the DNA is affected. 23 
Statistical analysis
The sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), and positive likelihood ratios (LR + ) were calculated. We used a χ 2 analysis or Fisher exact test to determine statistically significant associations ( α-level of 0.05.) IBM SPSS v 24 (IBM, Armonk, NY) was used for these analyses.
Results
Surgery and surveillance cohorts: Benign versus HGD/invasive
Of the 283 IMP cases (225 patients), 98 were followed by pancreatectomy, and the remaining 185 were followed by a minimum of 23 months' surveillance. There were 23 IMP cases associated with an HGD/invasive outcome determined by surgical pathology had a median time to diagnosis of 5.2 months after IMP. The other 260 cases had a benign outcome, as concluded by surgical pathology or surveillance at a median 3.6 months and 47.3 months after the determination of the IMP, respectively ( Table 1 ) .
The most sensitive predictor of HGD/invasive outcome was the presence of high-quantity DNA (sensitivity: 78%, P = .004). Highquantity DNA alone, however, was poorly specific (53%) and not an accurate (55%) predictor of HGD/invasive disease, with a poor PPV (13%). Thus, most HGD/invasive lesions exhibited high-quantity DNA, but many benign lesions exhibited this feature as well. The single most specific DNA factor for HGD/invasive disease was the presence of HC LOH (specificity: 98%, P = .003). Alone, HC LOH had a PPV of 50%, but occurred proportionally much more frequently in the HGD/invasive group with an LR + of 10. The combination of high-quantity DNA and HC LOH ( P = .006) provided greater specificity (99%), accuracy (91%), PPV (60%), and an LR + (15). An LR + of this value provided a posttest probability of HGD/invasive disease TP , true positive (n-positive/n-tested in malignant group); FP , false positive (n-positive/n-tested in benign group); Sn , sensitivity; Sp , specificity; Acc , accuracy; LR + , positive likelihood ratio; PPV , positive predictive value; NPV , negative predictive value; HC LOH , high clonality loss of heterozygosity of tumor suppressor genes; HC KRAS , high clonality KRAS mutation; high quantity + quality DNA = high-risk DNA.
greater than the pretest probability, and strongly suggested the possibility of a more aggressive disease. The combination of highquality DNA or high-risk DNA and HC LOH provided 100% specificity, > 90% accuracy, and a PPV of 100% ( P < .05). HC LOH, in addition to an HC KRAS mutation, was associated with HGD/invasive outcomes ( P = .011), with a specificity of 99% and accuracy of 91%. The presence of both KRAS and GNAS mutations, in addition to elevated quantity or quality of DNA, was associated with HGD/invasive disease ( P = .032), with moderate sensitivity (67%), high specificity (95%), accuracy (92%), and reasonable PPV (67%). DNA components reaching or approaching significant associations with HGD/invasive disease are summarized in Table 2 . Several other DNA components alone and in combination, which did not reach statistical significance for a high specificity for HGD/invasive outcomes, are presented in Supplemental Table  1 (for the online version).
Surgery cohort alone: Benign versus HGD/invasive
A total of 98 IMP cases were followed by surgery, with 23 HGD/invasive and 75 benign outcomes. High-quantity DNA ( P = .019) again was the most sensitive (78%) in determining HGD/invasive disease; however, the specificity (49%), accuracy (56%), and PPV (32%) were overall poor. High-quality DNA ( P = .019) and high-risk DNA ( P = .015) were less sensitive (48% and 44%) but more specific (77% and 81%), with greater accuracy (70% and 72%) and slightly improved PPV (39% and 42%) for HGD/invasive lesions. The combination of high-quality DNA with HC LOH ( P = .017) provided the greatest specificity (100%), accuracy (77%), and PPV (100%); however, this combination occurred rarely and lacked sensitivity (15%). In contrast to the surgery and surveillance cohort, HC LOH alone did not reach statistical significance ( P = .077), but suggested high specificity (95%) and accuracy (75%) for HGD/invasive outcomes , with a PPV of 57%. HC LOH in combination with high-risk DNA provided even greater specificity (100.0%), accuracy (76.0%), and PPV (100%), but did not reveal a significant relationship with HGD/invasive outcomes ( P = .068). Any degree of elevated DNA (high quantity + /-high quality), in addition to both KRAS and GNAS mutation, most closely approximated a statistically significant relationship with HGD/invasive disease ( P = .056), with fair sensitivity (67%), good specificity (93%), moderate PPV (67%), and the highest accuracy of any combination (89%). Furthermore, this combination of DNA components provided the highest LR + of 10, which greatly increases the post-test probability of HGD/Invasive disease when present ( Table 3 ) .
Several other DNA components and combinations did not reach statistical significance and are outlined in Supplemental Table 2 (for the online version).
Outcome predictions based on 2012 Consensus Guidelines criteria
When considering all patients with high-risk stigmata (HRS), worrisome features (WF) (excluding pancreatitis), and EUS findings, patients recommended for surgery, based on ICG (ICG + , n = 44) had a rate of HGD/invasive disease of 30%. When patients from the ICG + group with HRS were excluded to include only patients with WF, or more "borderline" lesions, (WF + , n = 111), the rate of HGD/invasive disease was 10%. Finally, patients lacking HRS or WF (ICG-, n = 158) had the least rate of HGD/invasive disease at 2%. Separate analyses were performed on these strata. In ICG + or WF + cases, HC LOH was associated with HGD/invasive disease ( P < .05), with high specificity ( > 98%) and moderate accuracy ( > 77%), with a PPV of 100% (ICG + ) and 67% (WF + ). HC LOH plus high-quality DNA ( P = .120) or HC KRAS ( P = .013) mutation in the WF + group provided 100% specificity and 100% PPV. The ICGgroup revealed no statistically significant relationships. The most compelling DNA feature was high-quantity DNA ( P = .118), with excellent sensitivity (100%) but poor specificity (52%) and accuracy (53%). Although the PPV of this DNA feature was poor (4%), the NPV reached 100%. These and other DNA analyses are summarized in Table 4 .
Discussion
IPMN are known to harbor malignant potential; but differentiating between low-and greater-risk lesions is difficult. In the era of individualized medicine, it is no surprise that the genetic profile of these cysts will be increasingly incorporated into clinical decisionmaking. Earlier studies have described the utility of cyst fluid DNA in predicting mucinous differentiation or malignancy of pancreatic cysts in general. To our knowledge, the present study is as of yet TP , true positive (n-positive/n-tested in malignant group); FP , false positive (n-positive/n-tested in benign group); Sn , sensitivity; Sp , specificity; Acc , accuracy; LR + , positive likelihood ratio; PPV , positive predictive value; NPV , negative predictive value; HC LOH , high clonality loss of heterozygosity of tumor suppressor genes; HC KRAS , high clonality KRAS mutation; high quantity + quality DNA = high-risk DNA.
the largest evaluation of the value of the DNA components for the IPMN-specific surgical and surveillance population. We found the most sensitive determinant of an HGD/invasive outcome was the presence of high-quantity DNA (78%). This finding is mechanistically plausible, because the development of cancer relies on the unregulated, disorganized growth and proliferation of cells. 24 As Khalid et al. 9 describe, however, certain benign processes, such as inflammation or necrosis, may lead to the release of cellular DNA, which may explain why high-quantity DNA is poorly specific but highly sensitive for HGD/invasive disease in our surgical and surveillance analyses. High-quality DNA was a predictor of HGD/invasive disease in the surgery-alone group, with greater specificity ( > 75%). DNA may degrade over time in a stagnant cyst or in the presence of a benign inflammatory process. Therefore, in the presence of rapid proliferation and the absence of benign inflammatory disease, the presence of high-quality DNA may suggest malignant processes.
Most earlier studies examining the role of KRAS mutation in predicting HGD/invasive pathology in all pancreatic cyst types have revealed no reliable association. 8,10 , 12 In the present study, we validated these earlier findings in our IPMN-specific population, because we found no significant relationship between KRAS mutation and HGD/invasive outcomes in our surgery and surveillance analyses. KRAS mutation only revealed predictive potential for HGD/invasive disease in the presence of concomitant mutations or elevated quantity or quality of DNA.
The presence of HC LOH was the most consistent predictor of HGD/invasive outcomes in the present study. HC LOH alone was highly specific for HGD/invasive IPMN (98%) in our analysis of surgery and surveillance patients, but when surgical patients were examined alone, although still highly specific, the association only approached statistical significance ( P < .08). Schoedel et al. 21 and Khalid et al. 10 have shown previously an association between KRAS mutations + LOH and HGD/invasive outcomes. Similarly, we demonstrated a statistically significant association between HC LOH + KRAS mutation and HGD/invasive outcomes in our surgery and surveillance analysis. In our surgical cohort, the combination of HC LOH and high-quality DNA provided 100% specificity for HGD/invasive outcomes. To our knowledge, this has not been documented previously.
In our subgroub analysis of ICG + , WF + , and ICG-patients, we found that the ability of DNA features to predict HGD/invasive disease varied, likely owed to differing prevalence of HGD/invasive outcomes in these strata. In practice, patients who are ICG + are frequently recommended for surgery; however, not all individuals are amenable to surgery or are optimal surgical candidates. In the ICG + and WF + subgroups, HC LOH again was highly specific for HGD/invasive disease with or without the presence of high-quality DNA or KRAS mutation, with a PPV 67%-100%. Therefore, the presence of HC LOH in patients who are ICG + but not optimal surgical candidates or have more borderline lesions (WF + ) should alert the clinician to a greater likelihood of HGD/invasive disease. For those lacking any HRS or WF (ICG-), the presence of high-quantity DNA provided 100% sensitivity with an NPV of 100%. Thus, the absence of high-quantity DNA only occurred in benign cases. Although this did not reach statistical significance, one may consider the absence of high-quantity DNA to support ongoing or potentially relaxed surveillance over surgery in this group. As the numbers in these subgroups were small, future studies are needed to validate these findings.
This study includes a specific subgroup of patients with IPMN who have undergone EUS-FNA, with resulting nonmalignant cytology and subsequent IMP testing. Cytology historically has shown high specificity but low sensitivity (65%) for detecting malignant IPMN. 25 Our data in combination with earlier studies demonstrate that DNA profiling may be useful in capturing more HGD/invasive IPMN when the gold standard of cytology fails.
Our study had several potential limitations. The number of HGD/invasive cases is relatively small ( n = 23). This is in part attributable to the exclusion of patients with preoperative cytology or core biopsy revealing high-grade atypia or adenocarcinoma for whom DNA profiling is not performed, because it would not enhance clinical decision-making. Thus, overtly malignant or aggressive lesions on imaging or by EUS-FNA cytology tend to either immediately undergo surgery or are self-selected out of the IMP testing process. Because of this, the power of our study is limited. Outcome data from molecular pathology and surveillance were gathered retrospectively to supplement our prospectively maintained IPMN database. It is plausible that a fraction of our surveillance cohort may contain non-IPMN cystic lesions. Although surgical pathology, cytology, or biopsy would ideally serve as the gold standard for diagnosis, patients without these diagnostic tests have less-definitive outcomes. We attempted to minimize the potential for misallocation to our benign versus HGD/invasive groups through the exclusion of patients with insufficient follow-up ( < 23 months) and imaging surveillance (radiographic or endoscopic) available at this 23-month point. Finally, the number of patients with specific DNA parameters is small and should be interpreted cautiously.
The present study is unique in a number of ways. Our evaluation of cyst fluid DNA components on an IPMN-specific population involves a large number of patients, which helps to provide internal validity for the application of these DNA parameters to IPMN specifically rather than pancreatic cysts in general. Most earlier studies exclude surveillance patients; we believe that the inclusion of nonsurgical patients in our study is more representative Table 4 Performance of DNA Features for Predicting HGD/Invasive Outcomes by Consensus Guidelines Subgroups. of the true IPMN population despite surgical pathology providing the most definitive means of determining an HGD/invasive or benign outcome. Therefore, the DNA measures with the strongest predictive power are likely to be reflected in the surgery population. We proposed several DNA profiles that may aid the clinician in decision-making, especially in cases of nondiagnostic cytology. The majority of HGD/invasive IPMN exhibit a high-quantity of DNA and can be considered the best candidate for a "screen" for this more advanced disease. This feature, however, is nonspecific. Many benign cysts also exhibit elevated levels of DNA. HC LOH alone and in combination with other DNA factors is associated most consistently with HGD/invasive outcomes with a high degree of specificity and should alert the physician to a greater probability of aggressive disease requiring resection. KRAS mutations only predicted HGD/invasive IPMN when combined with other DNA factors. Thus, the predictive role of KRAS mutation is less clear. Molecular profiling of pancreatic cyst fluid should not be used as a standalone test but can be useful as an adjunct to established diagnostic testing.
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Discussion
Dr R. Matthew Walsh (Cleveland, OH): Advances in our understanding of cystic neoplasms has led us to selective management in the majority of patients with cystic lesions, but we haven't been able to decide who is most appropriate for surgery since we don't know who is going to develop cancer. This is particularly true in the side branch IPMN group, but you also included main duct and mixed type in your group. The utilization of DNA analysis could be potentially very valuable since, as you mentioned, it is commercially available.
You selectively used both DNA analysis and surgery in your patient population. It would be good to know who got selectively the DNA analysis in your cohort and then follow that by how exactly surgery was selected in this group. The real value is how to use this independently to help manage the patient.
Did you use this independently in any particular patient, getting back to, again, how did you select the patients for surgery? If you were agnostic to the data and used conventional factors for resection, then this apparently has very little value because in your cohort observation group, no one developed cancer.
So, the results can be used independently to recommend surgery. Who exactly are you using it on now? Is it patients over 3 centimeters? Is it patients with worrisome features? Conversely, you could use this to perhaps recommend observation or even an extended period of observation in terms of interval between testing or potentially who should never get another imaging study. So, do you use it for that? Lastly, did you try and correlate your DNA analysis with IPMN subgroups, pathologic subgroups such as gastric type, intestinal type, or the oncocytic type?
Lastly, also, did you at all correlate with any germline mutations in this population? Dr Rachel Simpson: Thank you, Dr Walsh, for your thoughtful questions. To start off, how do we determine who gets the endoscopic DNA profiling? How do we use it clinically? It kind of depends on the patient. Sometimes they see the gastroenterologist first, and a lot of times they are going to get it regardless if they see a cyst in the pancreas. When we are seeing them in clinic, it depends on if they have a borderline lesion that we're not sure about. But typically, patients with a very small cyst, a solitary cyst with no solid components, and we are really not worried about it, oftentimes they won't get this type of sampling.
How do we use this sort of data? The data I presented were the DNA components alone, and that's not how we've been using it in clinic to date. When it's commercially available, we get a report from the company, and it gives you an aggregate malignancy risk score. This is problematic for two reasons. The commercial test is generalized to all cyst types, which makes it difficult for us to know how to apply the results to the IPMN population, which is mostly what we see in clinic.
Secondly, it's integrated with what we see as some questionable clinical data that may not be applicable to IPMN but more cysts in general. So that makes it difficult for us to know when we see these mutations listed on the report how important they are in predicting malignancy.
In general, we're still reliant on clinical and radiographic features and the consensus guidelines to guide our management, but when we get a report that says you have an aggressive lesion, that might push us more towards surgery or very close surveillance in a patient that may not otherwise have such aggressive management. That's how we're using it to date. I think seeing these data opens our eyes, especially to something like the loss of heterozygosity of tumor suppressor genes, that those patients are much more likely to have a malignant or an aggressive lesion than a benign lesion.
How would I recommend using this test or these data? For patients with high-risk stigmata by the consensus guidelines or obvious main-duct involvement, it's not as useful and I don't think it would change clinical management because most surgeons agree that those patients should undergo surgical resection.
I think it's mostly beneficial in patients with the borderline lesions maybe growing beyond 3 centimeters, thickened cyst walls, thick septations, nonenhancing nodules where we're not really sure how to manage them, especially in the patient that is not a good surgical candidate. But, if you see some of these high-risk DNA features that are very specific for malignancy, that might push you to either watch them much more closely or advance towards surgery.
Furthermore, I pointed out that many of these are not very sensitive for malignant or invasive IPMN, however, high-quantity DNA was almost 80% sensitive for malignancy. In a patient with a very small cyst with no solid components, if you see that they have a low quantity of DNA, that might reassure you a little bit more that you can extend your surveillance period and move away from a surgical management plan.
Finally, did we correlate our findings with any pathologic subtypes? Unfortunately, no, we did not. That wasn't the main objective of our study. With the small number of patients that had certain DNA mutations, we wouldn't have enough patients to have usable results. But that would be a good idea for a future, larger multi-institutional study.
Dr Timothy Pawlik (Columbus, OH): I have one question and one comment. Largely, your data and your findings focused around sensitivity and specificity. But for screening tests, what we're interested in is positive predictive value and negative predictive value. Sensitivity and specificity are more if someone has a disease or if someone does not have a disease, is the test positive or negative? But really for IPMNs, what we're interested in is if the test is pos-itive or if the test is negative, do they have the disease or do they not?
I would encourage you to report the negative predictive value and the positive predictive value in your paper, because I think that would be more informative with regards to how these could be used in a true screening way.
My question is, Did you look at the positive predictive value and the negative predictive value? If so, can you share that with us?
Dr Rachel Simpson: So, at the very beginning, that is how we calculated our results. But then, in looking at the fact that predictive values are so heavily reliant on the prevalence of disease, and we had such low numbers of malignant and invasive outcomes, we felt like our data might be more meaningful to report sensitivity and specificity, but that's something to consider.
Dr Timothy Pawlik (Columbus, OH): Could you just comment on the clinical application in light of if the prevalence being very low and if the positive and negative predictive values are low, can this be used as a screening tool? Dr Rachel Simpson: I don't remember the actual values of the positive predictive and negative predictive values. So, I can't comment on, for example, if high clonality or loss of heterozygosity had great positive predictive value. I don't know that off the top of my head.
But something else we looked at was the positive likelihood ratio, which doesn't then rely on the prevalence of disease. It takes into consideration sensitivity and specificity. And some of them were very high, like high clonality, loss of heterozygosity, positive likelihood ratio is 10. So, you are 10 times more likely to have a malignant lesion than a benign lesion if you have that DNA feature. That's something we should look at and consider.
